Last reviewed · How we verify
Budesonide inhalation suspension
Budesonide is a corticosteroid that reduces inflammation in the airways by binding to glucocorticoid receptors and suppressing inflammatory mediator production.
Budesonide is a corticosteroid that reduces inflammation in the airways by binding to glucocorticoid receptors and suppressing inflammatory mediator production. Used for Asthma maintenance therapy in children and adults, Croup (laryngotracheobronchitis).
At a glance
| Generic name | Budesonide inhalation suspension |
|---|---|
| Also known as | Pulmicort Respules, Pulmicort Respules®, inhaled corticosteroids |
| Sponsor | AstraZeneca |
| Drug class | Inhaled corticosteroid |
| Target | Glucocorticoid receptor |
| Modality | Small molecule |
| Therapeutic area | Respiratory/Pulmonology |
| Phase | FDA-approved |
Mechanism of action
Budesonide acts as a selective glucocorticoid receptor agonist that decreases airway inflammation by inhibiting the release of inflammatory cytokines, chemokines, and adhesion molecules. When delivered as an inhalation suspension, it deposits directly in the lungs, providing local anti-inflammatory effects with minimal systemic absorption. This reduces airway hyperresponsiveness and mucus production in asthma and other obstructive airway diseases.
Approved indications
- Asthma maintenance therapy in children and adults
- Croup (laryngotracheobronchitis)
Common side effects
- Tremor
- Headache
- Nervousness
- Oral candidiasis
- Hoarseness
- Throat irritation
Key clinical trials
- A Study to Evaluate the Effect of Budesonide, Glycopyrronium, Formoterol Fumarate (BGF) Metered Dose Inhaler (MDI), Budesonide and Formoterol Fumarate (BFF) MDI and Placebo MDI on Exercise Parameters in Participants With Chronic Obstructive Pulmonary Disease (COPD). (PHASE3)
- A Study Evaluating the Efficacy of Budesonide, Glycopyrronium and Formoterol Fumarate Metered Dosed Inhaler on Cardiopulmonary Outcomes in Chronic Obstructive Pulmonary Disease (PHASE3)
- A Study to Investigate the Effect on Lung Function of BDA Formulated With a Next Generation Propellant Compared With an Approved Asthma Treatment (BDA With HFA Propellant) in Participants With Asthma (PHASE3)
- Change in Patient-repOrted Outcomes in COPD Patients Newly Initiated on TRIXEO AEROSPHERE in Real worlD
- Study to Assess the Lung Exposure Bioequivalence of Budesonide, Glycopyrronium, and Formoterol Delivered by BGF MDI With Next-Generation Propellant Compared With BGF MDI With HFA Propellant (PHASE1)
- A Study to Assess the Total Systemic Exposure Bioequivalence of of Budesonide, Glycopyrronium, and Formoterol Delivered by BGF MDI With Next-Generation Propellant Compared With BGF MDI With HFA Propellant (PHASE1)
- A Study to Assess the Pharmacokinetics and Safety of Budesonide, Glycopyrronium, & Formoterol (BGF) Metered Dose Inhaler (MDI) With a Next-Generation Propellant (NGP) With a Spacer, BGF MDI Hydrofluoroalkane (HFA) With a Spacer, as Well as BGF MDI NGP Without a Spacer (PHASE1)
- A Comparison of PT027 vs PT007 Used as Needed in Participants With Asthma (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Budesonide inhalation suspension CI brief — competitive landscape report
- Budesonide inhalation suspension updates RSS · CI watch RSS
- AstraZeneca portfolio CI